Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors

Next Previous
Trial Profile

An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant-mesothelioma; Oesophageal cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms INSIGHT; INSIGHT Stratum D; INSIGHT-004; INSIGHT-005

    • Most Recent Events

    • 04 Jan 2024 According to an Immutep Limited media release, company announced that the first patient has been enrolled and safely dosed in this trial.
    • 03 Aug 2023 Number of treatment arms changed to 5, Planned number of patients changed from 45 to 110.
    • 03 Aug 2023 Planned End Date changed from 30 Jun 2024 to 30 Sep 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top